EGFR has been shown to be a key molecule in the pathogenesis of rectal cancer, and its expression in the tumor of LARC patients undergoing neoadjuvant therapy was associated with significantly lower DFS [36,38]. This evidence concerns the gene EGFR and rectal cancer.